terms of both normal and aberrant T lymphocyte activation.
Our current understanding of the mechanisms of The highly complex pattern of expression of major MHC-II gene expression results to a large extent from the histocompatibility complex class II (MHC-II) molecules study of various regulatory mutant cell lines, affected in determines both the immune repertoire during developcertain essential MHC-II regulatory factors (Griscelli et al. , ment and subsequently the triggering and the control 1989; Mach et al., 1994) . In particular, analysis of cell of immune responses. These distinct functions result lines from patients suffering from hereditary MHC-II from cell type-restricted expression, developmental deficiency (also called bare lymphocyte syndrome; BLS), control and either constitutive or inducible expression a genetically heterogeneous disease of gene regulation, of MHC-II genes. Yet, in these various situations, has led us to the discovery of three distinct, MHC-II-MHC-II gene expression is always under the control specific, transacting factors: RFX-5, RFX-AP and CIITA. of a unique transactivator, CIITA. Here we show Each of these factors is essential for the expression of all that the CIITA gene is controlled by several distinct MHC-II genes and, in all three cases, mutations in the promoters, two of which direct specific constitutive relevant regulatory genes could be identified in BLS expression in dendritic cells and B lymphocytes respectpatients. RFX-5 and RFX-AP (RFXively, while another mediates γ-interferon-induced associated protein) (Durand et al., 1997) are components expression. Thus the cellular, temporal and functional of the multi-subunit RFX complex (Reith et al., 1988 ) diversity of MHC-II expression is ultimately controlled that binds specifically to the X box of all MHC-II by differential activation of different promoters of a promoters.
single transactivator gene. This provides novel experi-
The MHC-II transactivator CIITA ) mental tools to dissect compartment-specific gain or has been found to act as a master-regulator of MHC-II loss of MHC-II function in vivo. 1993, 1994) . CIITA and MHC-II expression are not only qualitatively but also quantitatively correlated (L.Otten, The level of major histocompatibility class II (MHC-II) V. Steimle, S.Bontron and B.Mach, in preparation) . In expression directly influences T-lymphocyte activation.
Introduction
addition to its essential role in constitutive MHC-II expresThe highly complex regulation of MHC-II expression thus sion, CIITA is also the obligatory mediator of IFN-γ-controls both the generation of the immune repertoire and inducible MHC-II expression, since IFN-γ induces CIITA the triggering and maintenance of an immune response expression which in turn activates MHC-II transcription (Benacerraf, 1981; Janeway et al., 1984) . It also represents . Furthermore, in plasmocytes, which an interesting example of a tight and complex control of are MHC-II negative, it was shown that CIITA expression a multi-gene family. Two main modes of MHC-II expresis abolished and that re-expression of CIITA is sufficient sion can be distinguished, constitutive or inducible.
to reactivate MHC-II expression in these cells (Silacci MHC-II genes are expressed constitutively in only a very et al., 1994) . In most cell types, introduction and expression restricted number of cell types, specialized in antigen of the CIITA gene is sufficient to activate expression of presentation, such as dendritic cells and B lymphocytes.
all MHC-II genes (Mach et al., 1996) . Within these cell lineages, MHC-II expression is also These examples demonstrate that control of MHC-II subject to strict developmental control. For example, in expression is ultimately dependent on the control of the murine B-lymphocyte compartment, early pro-B cells expression of the CIITA gene itself. It was therefore an are MHC-II negative, expression in pre-B cells is inducible obvious challenge to explore the mechanisms that regulate by interleukin-4 (IL-4), mature B-cells show constitutive CIITA expression in various cell types and biological MHC-II expression, while terminal differentiation into plasma cells is accompanied by the extinction of MHC-II situations and thus to understand how a single rate-limiting the CIITA gene (see below). CIITA type I, III and IV 5Ј sequences were identified in human and mouse genomic transactivator controls the highly complex pattern of DNA, while the CIITA type II 5Ј end was found only in regulation of MHC-II genes, including constitutive and human DNA. inducible expression. We show here that expression of Of the four different forms of CIITA transcripts which CIITA is controlled, in an unexpected manner, by four where thus identified, human CIITA type III corresponds independent CIITA promoters leading to CIITA transcripts to the previously described form of CIITA cDNA (Steimle with four distinct first exons. The individual CIITA proet al., 1993) . The four transcripts share a common open moters are used in an alternative and tissue-specific reading frame starting from the AUG which is located manner. Distinct CIITA promoters control either MHC-II 21 bp downstream of the 5Ј end of the common nucleotide constitutive expression in dendritic cells (promoter I, PI) sequence (Figure 1 ). For CIITA forms II and IV, this and in B lymphocytes (PIII), or IFN-γ-inducible expression AUG, located in the context of a perfect Kozak consensus (PIV) in a variety of MHC-II-negative cell types. We (Kozak, 1989) , is the first initiation codon (Figures 1 and conclude that the cellular, temporal and functional diversity 3B and D). CIITA forms I and III display, in addition, in MHC-II expression is not regulated at the level of the upstream AUGs in favourable translation initiation con-MHC-II genes themselves, but is ultimately under the texts, which potentially lead to CIITA proteins with an control of several promoter sequences that activate differadditional 101 or 24 N-terminal amino acids respectively entially the same transactivator gene.
( Figures 1 and 3A and C). These features are shared between human and murine CIITA 5Ј ends I, III and IV. The respective nucleotide conservation within these
Results
different CIITA 5Ј ends is 75, 68 and 66%. For the sake Multiple 5Ј ends of CIITA mRNA of coherence and clarity, we propose to maintain the When the murine homologue of human CIITA (Steimle numbering of the amino acid sequence of the body of the et al., 1993) was isolated from a mouse cDNA library CIITA sequence as published originally for CIITA type by low stringency hybridization (L.Otten, V.Steimle, III . S.Bontron and B.Mach, in preparation), sequence comSince the nucleotide sequences of the 5Ј region of all parison between human and mouse CIITA cDNAs showed four different CIITA mRNAs differ, they could be generexcellent identity downstream of position ϩ167 of the ated either by alternative splicing of different 5Ј exons in human CIITA cDNA, but totally divergent 5Ј ends. To the CIITA gene or by a differential usage of four different establish the structure of the 5Ј region of CIITA mRNA, promoters. Complete lack of sequence homology at the a systematic analysis of CIITA 5Ј ends was performed by very 5Ј ends of the divergent sequences favoured the RACE-PCR both on murine and human RNAs isolated second hypothesis. from different tissues, using primers from the homologous region (Figure 1 ). These assays led to the isolation of four Genomic organization of the 5Ј-flanking region of the CIITA gene different CIITA cDNA 5Ј sequences in human and three in mouse. Sequence analysis revealed that all these different A human and a murine genomic λ phage library were screened using DNA fragments from the human type III cDNA clones had identical 3Ј ends but different 5Ј ends. In each case, the boundary between the diverging 5Ј ends and the murine type I and III 5Ј ends of CIITA cDNAs, respectively. Three overlapping human genomic clones and the common 3Ј ends was located, in human and mouse, 21 nucleotides upstream of the second ATG and five overlapping murine genomic clones covering 24 and 35 kb were obtained, and a detailed restriction map codon of the CIITA cDNA sequence described previously (Figure 1 ). The different CIITA 5Ј was established (Figure 2 ). Fragments hybridizing to the four different 5Ј ends were identified, subcloned and and PIV) located upstream of four different CIITA exons 1 (of type I, II, III and IV respectively) (Figure 2 ). sequenced. In all cases, the genomic sequence corresponded exactly to the sequences of the different 5Ј ends of CIITA cDNA clones and thus represented distinct Analysis of promoter sequences exons. Furthermore, the nucleotide sequences of exonComparison of the sequences of the four different CIITA intron boundaries agreed with consensus splice donor promoters showed no significant homology to each other, sequences (Breathnach and Chambon, 1981) . Screening both in human and mouse. None of the regions upstream of the murine genomic clones with a human CIITA type of the different CIITA first exons contains a consensus II 5Ј end cDNA probe did not yield a positive signal. The TATA box element or GC box. The absence of a TATA four different 5Ј exons (i.e. exon 1 of CIITA mRNA I, II, box is consistent with the finding that there are multiple III and IV respectively) were mapped within the 5Ј-initiation start sites (Breathnach and Chambon, 1981) . In flanking region of the CIITA gene. The distance between contrast, comparison of the homologous CIITA promoters exon 1 of CIITA type I and exon 1 of CIITA type IV is between human and mouse showed significant sequencẽ 13 kb in human and 10 kb in the mouse. The relative homology. For CIITA promoters I, III and IV, this homoorder and, in part, the genomic distances between homology extends over 120, 800 and 350 nucleotides respectlogous promoters are maintained between the two species, ively ( Figure 3 ). More interestingly, within these promoter indicating a strongly conserved genomic organization regions, small segments that are very well conserved ( Figure 2 ).
within the two species could be identified ( Figure 3 ). This sequence conservation suggests functional relevance and Multiple transcription initiation sites reveal four potential cis-acting elements. On the basis of this strong distinct CIITA promoters human-mouse conservation, as well as on the basis of The transcription initiation sites of the different human sequence homology with known cis-acting elements, the CIITA mRNAs were mapped by RNase protection assays following potential cis-acting elements of the different with fragments covering the different CIITA exons 1 and CIITA promoters can be pointed out. their respective 5Ј-flanking regions. For CIITA type I, CIITA promoter I contains an NF-GMb site (Shannon three protected fragments were detected using mRNA et al., 1988) , an NF-IL6 site (Akira and Kishimoto, 1992) , from liver (data not shown). The major protected fragment two NF-IL6 inverted sites, a PEA3 site ( box (Murre et al., 1989) , an IRF1/2 site (Tanaka et al., For CIITA type III, several protected fragments were 1993), an MYC inverted site (Agira et al., 1989) and an obtained using mRNA from a B-lymphocyte cell line OCT inverted site (Rosales et al., 1987) in human and (data not shown). The major transcription initiation site mouse, respectively, as well as two CCAAT boxes in located 183 bp upstream of the 3Ј end of exon 1 defines mouse ( Figure 3C ). position ϩ1 of CIITA type III mRNA ( Figure 3C ). Two CIITA promoter IV, the IFN-γ-responsive promoter (see other main initiation start sites are located at positions below), contains a NF-GMa site (Shannon et al., 1988) , -8 and -4, and several minor sites from positions -23 to a GAS box (Pellegrini and Schindler, 1993) , an adjacent ϩ34. The longest CIITA type III cDNAs obtained by E box (Blackwell et al., 1990) and an IRF1/2 site, both RACE-PCR fit with these initiation start sites. The CIITA in human and mouse ( Figure 3D ). In addition, there is an cDNA sequence initially described NFκB site (Sen and Baltimore, 1986) in human and two begins at position ϩ17.
AP1 sites in mouse. Although it is beyond the scope of For CIITA type IV, multiple fragments were protected, this report, a systematic functional analysis of the role of using mRNA from an IFN-γ-induced melanoma cell line, these various potential cis-acting motifs is obviously with the major transcription initiation site located 75 bp required. upstream of the 3Ј end of exon 1 (data not shown). This defines nucleotide ϩ1 of CIITA type IV mRNA ( Figure  3D ). A second major and six minor transcription initiation Differential usage of the multiple CIITA promoters To study the pattern of expression of the different forms sites were identified at position ϩ17 and between positions -54 and ϩ69 of exon 1 of CIITA type IV, respectively. of CIITA mRNAs, and thus of the different CIITA promoters, RNase protection analyses using probes specific The 5Ј ends of many CIITA cDNAs obtained by RACE-PCR coincide with these initiation sites. No tissue or cell for each type of CIITA mRNA were performed ( Figure  4A) . A panel of different tissues and cell lines expressing line could be identified so far in which the CIITA type II 5Ј end is expressed at a significant level; the exact initiation the CIITA gene either constitutively or following IFN-γ induction were analysed. The results were quantified by site of this form of CIITA transcript was, therefore, not analysed further.
PhosphorImager. Interestingly, there is a striking difference in the specific usage of each of the different CIITA Since all types of CIITA mRNAs were transcribed from multiple transcription initiation sites, we can conclude that promoters. CIITA type I mRNA, resulting from the use of promoter I, is expressed at a remarkably high level in these sites represent bona fide 5Ј ends of transcription products from four distinct CIITA promoters (PI, PII, PIII dendritic cells (Figures 4B and 5) . It is barely detectable in spleen and thymus, and no other tissue or cell line CIITA type IV mRNA is the major form expressed following induction by IFN-γ. This was observed in could be identified in which CIITA type I was expressed.
The presence of CIITA type III mRNA is detected at a different IFN-γ-inducible cell lines, such as melanoma (Me67.1), monocytes (THP1), endothelial cells (HUVEC) high level in different B-lymphocyte cell lines, as well as in tissues rich in B lymphocytes such as spleen and tonsils, and fibroblasts (PP2) ( Figure 4C , lower panel, and Figure  5 ). In contrast, only a low level of type IV CIITA transcript and also in the thymus ( Figure 4C , upper panel, and Figure 5 ). In contrast, type III mRNA was detected only was detectable in B lymphocytes or in dendritic cells ( Figure 4C , upper panel, and Figure 5 ). No cell line or at a low level in dendritic cells and even less so in a variety of IFN-γ-induced cell lines ( Figures 4C and 5) .
tissue could be identified to date in which a significant amount of CIITA type II mRNA is detectable by RNase 6, lane 5). As a control, nascent RNA from a B-lymphocyte cell line (Raji), which expresses CIITA constitutively, was protection assay (data not shown). The quantification of the differential expression of the different CIITA analysed ( Figure 6 , lane 1). The level of nascent RNA was similar in the B-cell line and in IFN-γ-induced THP1 transcripts, from their respective endogenous promoters, is represented schematically in Figure 5 , and the percentcells. These results show that the induction of the CIITA gene by IFN-γ is controlled mainly at the level of ages of relative promoter usage are indicated in Table I. transcription. Moreover, no nascent RNA could be detected in a T-lymphoma cell line (CEM) constitutively negative Differential CIITA expression is under transcriptional control for CIITA expression (data not shown). The constitutive expression of CIITA RNA is thus also controlled at the To determine if the expression of the CIITA gene is controlled at the level of transcription, an alternative level of transcription. Comparison of lanes 5 and 6 shows that the relative amount of CIITA RNA versus TATA method to the classical run-on assay was carried out for the analysis of the transcription rate of CIITA RNA.
box-binding protein (TBP) RNA is completely different between nascent RNA and nuclear RNA. This excludes any Nascent RNA chains were isolated from nuclei by precipitation of a chromatin pellet containing DNA, histones and contamination of the nascent RNA chains by nuclear RNA. ternary transcription complexes (Wuarin and Schibler, 1994 ). Nascent RNA chains were then isolated from the The promoter-proximal regions control alternative usage of different CIITA promoters chromatin pellet and analysed by RNase protection assays.
The transcription rate of the CIITA gene was analysed The functional activity and tissue specificity of CIITA promoters III (PIII) and IV (PIV) were analysed by in the monocyte cell line THP1 before and after induction by IFN-γ. Before induction, no CIITA nascent RNA could transient transfection assays of promoter-reporter gene constructs. Since CIITA type III mRNA is the major form be detected (Figure 6, lane 3) . After induction by IFN-γ, CIITA nascent RNA was detected at a high level ( Figure  expressed in B lymphocytes and CIITA type IV mRNA 6 . Analysis of transcription from CIITA promoters III and IV. Nascent RNAs (lanes 1, 3 and 5) and free nuclear transcripts (lanes 2, 4 and 6) were analysed by RNase protection assays in B lymphocytes (Raji), and in monocytic cells (THP1) before (-) and after (ϩ) induction by IFN-γ. The RNAs were hybridized with the internal CIITA probe, the TBP probe and the CIITA type III or type IV probe for Raji and THP1, respectively. the same CIITA promoter IV was highly induced by IFN-γ after IFN-γ induction. These results provide functional evidence for the existence of distinct CIITA promoter regions, located immediately upstream of the alternative is expressed preferentially in IFN-γ-induced cells, the B-lymphocyte cell line Raji and the melanoma cell line 5Ј exons type III and IV. They also showed that the use of these two distinct CIITA promoters is indeed controlled Me67.8 were chosen for these functional assays. Because of the very low level of expression of the CIITA gene in a tissue-specific manner, either constitutively or following induction, as observed earlier for the transcription of , it was necessary to use a highly sensitive reporter gene assay, such as quantitative RTthe endogenous CIITA gene into distinct CIITA mRNA. PCR transcription assay (Sperisen et al., 1992) . For both CIITA promoters PIII and PIV, two different fragment Discussion sizes were analysed and compared with the promoterless plasmid pGβG(ϩ) as a negative control. Transfections of
The very complex and tight regulation of expression of the MHC-II gene family has direct implications for pIII-974 and pIII-322 in B lymphocytes revealed a high activity of CIITA promoter PIII, whereas in Me67.8 cells, T-lymphocyte activation and thus for the control of the immune response. In addition, significant pathophysiothe same promoter PIII was inactive, before and after induction by IFN-γ ( Figure 7A ). In B lymphocytes, the logical consequences such as immunodeficiency or aberrant T-cell activation may arise from the disregulation activity of the short pIII-322 promoter was higher than that of the longer promoter pIII-974 (signal ratios of 8.2 of MHC-II gene expression. The unsuspected findings reported here allow us to attribute the tissue-specific and and 2.6 respectively). The control pGβG(ϩ) was negative in both cell types.
temporal control of expression of MHC-II molecules, and hence of T-cell activation, to the selective usage of distinct In contrast, the CIITA promoter IV (pIV-950 and pIV-461) showed only a baseline activity in B lymphocytes alternative promoters of the regulatory gene CIITA. This indicates that the complex pattern of regulation that (Raji) (signal ratios of 0.4 and 1.1 respectively), whereas Expression of MHC-II molecules can be modulated by a number of different stimuli including immune, neuroendocrine and even viral mediators (Glimcher and Kara, 1992; Mach et al., 1996) . On a restricted number of specific cell types, one observes up-or down-regulation of MHC-II expression, occasionally with opposite effects of certain mediators depending on the target cell. Within this highly complex pattern, MHC-II regulation is characterized by constitutive expression in professional APCs, such as dendritic cells and B lymphocytes, and inducible expression in non-professional APCs, in particular by IFN-γ. Yet, in all these cases, the control of MHC-II expression is directly dependent on the expression of the same transactivator, CIITA. We have shown here that tissue-specific expression of this transactivator is controlled by distinct promoters and that individual CIITA promoters, in different cell types and after different signals (Figure 8 ). Additional levels of complexity might be promoters control MHC-II expression in professional versus non-professional APCs. It follows that the conintroduced through differential post-transcriptional control operating on distinct CIITA transcripts. trolled expression of a family of target genes, with its cellular and developmental specificity and with its different A systematic analysis of CIITA mRNA expression in different tissues by RACE-PCR led to the discovery of functional consequences, ultimately is exercised by alternative activation of individual promoters of the CIITA four different 5Ј exons (Figures 1 and 3) . Each of the four alternative first exons of CIITA is spliced to a common gene. We suggest that this multi-promoter system has been developed to allow the fine regulation of CIITA expression exon 2. The first exon of CIITA mRNA type I and III each encodes an additional upstream AUG, in-frame with by different transcription factors operating on alternative the common AUG located in exon 2, which is the first CIITA promoter contains a conserved consensus GAS AUG for CIITA type II and IV. Therefore, the alternative box. This is compatible with the known involvement of expression of CIITA mRNA can lead to three different STAT1 in the induction of MHC-II genes by IFN-γ (Meraz forms of CIITA protein. Interestingly, comparison of et al., 1996) . It also contains a conserved IRF1-binding human and mouse nucleotide and amino acid sequences site, which is a factor involved in the regulation of several of the first exon of CIITA type I indicates a relative excess genes induced by IFN-γ (Briken et al., 1995) . The study of mutations at the third base position of the codon, a of mutant cell lines specifically mutated in the responssituation that favours conservation at the amino acid level.
iveness of the CIITA gene to IFN-γ will be of great interest This suggests evolutionary pressure for conservation of in the search for trans-acting factors acting selectively on this sequence and thus translation of this segment. We CIITA promoter IV. One can also anticipate an interest in have not observed differences in the biological activities possible polymorphisms within the CIITA promoters. For of CIITA initiated at either the common AUG or the first instance, small differences in the responsiveness to IFN-γ AUG of the type III transcript in transfection experiments in terms of CIITA and MHC-II induction, and thus (V. Steimle et al., unpublished data) , but this possibility ultimately in terms of the magnitude of the T-cell response, needs to be explored further, especially for CIITA type I, would be expected to have important functional since it may give rise to an additional level of complexity implications. in the fine tuning of CIITA function.
Alternative promoters have been identified in several The pattern of CIITA promoter usage was analysed by eukaryotic genes. Their differential usage can afford an RNase protection assays on the specific transcripts of extra level of flexibility in the regulation of these genes the endogenous CIITA gene. Surprisingly, this analysis (Schibler and Sierra, 1987 ; Ayoubi and Van De Ven, revealed a strong bias in the selective use of each of the 1996). One promoter, for example, can be functional in a different CIITA promoters, with two different kinds of given tissue or during a particular developmental stage. specificities. First, there is a tissue-specific use of two Gene transcription from multiple promoters allows differdistinct constitutive promoters (PI and PIII), with a preferential post-transcriptional control, since RNA transcripts ential use of promoter I in dendritic cells and of promoter with different 5Ј-untranslated regions could exhibit differ-III in B lymphocytes. Second, distinct CIITA promoters ent stability or different translational efficiency (Kozak, are used for constitutive (PI and PIII) versus IFN-γ-1991) . The unique features of the system described here inducible (PIV) expression of the regulatory gene, with concern the hierarchy in the control of a family of target the preferred utilization of promoter IV in cells activated genes, with its highly complex pattern of regulation and by IFN-γ (Figures 4 and 5 , Table I ). Direct transcription diverse functional consequences, by a single regulator assays confirmed that the control of both constitutive and gene, itself controlled by selective activation of alternative inducible expression of CIITA is indeed largely executed promoters. at the level of transcription (Figure 6 ). This reinforces the Finally, it is worth pointing out that the unexpected importance of multiple promoters in the control of CIITA finding of alternative usage of different CIITA promoters gene expression.
for constitutive versus inducible expression suggests novel Functional analysis of CIITA promoters III and IV strategies of immunomodulation. First, it is remarkable showed that the region immediately upstream of the that CIITA promoter I is expressed selectively in dendritic respective first exons does confer tissue-specific expression cells. This may provide an experimental model for conof a reporter gene construct (Figure 7) . Indeed, PIII-322 trolled expression of genes in dendritic cells in vivo, a shows a specific expression in B lymphocytes, while point of interest in the study of the immune system, as PIV-461 is functional only in IFN-γ-induced cells. It is well as for DNA vaccination, given the scarcity of known remarkable that, in both cases, a small upstream region dendritic cell-specific promoters. Second, it will allow us proximal to the initiation start site is sufficient to confer selectively to modulate the expression of CIITA, and thus tissue specificity or inducibility by IFN-γ, as was observed of MHC-II molecules, in vivo in a conditional fashion by for the expression of the endogenous CIITA gene. In view inducing selective recombination within specific CIITA of the short genomic distance between CIITA promoters promoters. For instance, while maintaining normal expres-III and IV, it will be interesting to explore whether, in sion of MHC-II molecules on professional APCs, it certain cases, they can act on each other as enhancers. An will be possible to repress selectively inducible MHC-II effect over that distance might explain the low level of expression, with both spatial and temporal control. The CIITA type IV transcript found in B lymphocytes and that potential selectively to prevent or trigger MHC-II expresof CIITA type III mRNA observed in induced cells sion in dendritic cells alone, or in B lymphocytes, also (Figures 4 and 5, Table I ).
offers interesting possibilities of immunomodulation Whereas no common features were observed between in vivo. Such novel forms of controlled experimental the different CIITA promoters within a given species, there modulation of MHC-II genes are relevant to studies of is a striking sequence conservation between homologous the development of the immune repertoire as well as to promoters in human and mouse (Figure 3) . Detailed studies on the pathogenesis of several inflammatory or sequence comparison of promoters I, III and IV in both autoimmune syndromes. Third, the distinct role of different species points to highly conserved sequence elements, CIITA promoters should eventually make possible the suggesting functional relevance and pointing to possible identification of agents capable of selectively inhibiting targets for DNA-binding proteins. A systematic study, MHC-II expression on certain cell types, such as nonincluding functional assays, will be required to dissect the professional APCs. Selective immunosuppression of this relevant cis-acting elements of each of the different CIITA promoters. It is worth pointing out that the IFN-γ-inducible type could be of clinical interest.
Isolation of nascent RNAs

Materials and methods
Nascent RNAs and free nuclear RNAs were isolated from 200ϫ10 6 cells as described (Wuarin and Schibler, 1994) . Isolation of nuclei was Cell lines and culture performed as reported earlier . Nascent RNA and The cell lines Raji [Epstein-Barr virus (EBV)-positive Burkitt lymphoma free nuclear RNA were treated with RNase-free DNase I (Boehringer). cell line], Mann (EBV-transformed human B-lymphocyte cell line), CEM Nascent RNA and free nuclear RNA isolated from 5ϫ10 6 and 1.25ϫ10 6 (T-lymphoblastoid cell line), THP1 (monocytic cell line) and PP2 cells, respectively, were analysed by RNase protection assay. (foreskin primary fibroblasts, provided by J.-M.Dayer), Me67 (melanoma cell line, provided by S.Carrell) and HUVEC (human umbilical cord vein endothelial cells, a gift from J.-L.Magnenat), were grown in RPMIReporter gene assay 1640 medium supplemented with 10% fetal calf serum, 10 U/ml Four CIITA promoter-reporter gene plasmids were constructed by penicillin, 10 mg/ml streptomycin and 2 mM L-glutamine and incubated subcloning CIITA 5Ј-flanking regions upstream of the rabbit β-globin at 37°C in 5% CO 2 . IFN-γ (500 U/ml for Me67, 1000 U/ml for THP1, gene of plasmid pGβG(ϩ) (Sperisen et al., 1992) . Plasmids pIII-974 PP2 and HUVEC) was added for induction experiments during the time and pIII-322 contain the -974 (NheI)/ϩ101 (HpaII) and the -322 (PstI)/ specified in the figure legends. BC1 dendritic cells were kindly provided ϩ101 (HpaII) fragments, respectively, of the CIITA 5Ј-flanking region as a frozen pellet by A.Lanzavecchia (Sallusto and Lanzavecchia, 1994) .
of exon 1 type III. Plasmids pIV-950 and pIV-461 contain the -950 (XhoI)/ϩ75 and the -461 (KpnI)/ϩ75 fragment, respectively, of the 5Ј-flanking region of exon 1 type IV.
RNAs
Reporter gene expression was measured by quantitative RT-PCR Total RNA from BC1 was prepared with Trizol reagent (Gibco-BRL).
as previously described (Sperisen et al., 1992) with the following Cytoplasmic RNAs from Raji, Mann, Me67.1, THP1, HUVEC and PP2 modifications. Raji (5ϫ10 6 ) and Me67.8 (2.5ϫ10 6 ) cells were transiently were extracted as described (Wilkinson, 1988) . RNA from human spleen, transfected by electroporation at 250 V, 960 μF (Genepulser, Bio-Rad), thymus, tonsil and kidney were a gift from P.Sapino.
with 20 μg of plasmid DNA and 400 μg of Escherichia coli tRNA as carrier in 750 μl of RPMI medium. Plasmid DNA is composed of a RACE-PCR defined ratio of a CIITA promoter-rabbit β-globin gene construct and RACE-PCR (Frohman et al., 1988) was carried out on total RNA from of reference plasmid. The latter contains a rabbit β-globin gene with a Raji, IFN-γ-induced Me67 and kidney with a RACE-PCR-kit (Gibco-40 bp deletion in the second exon and is transcribed under the control BRL) according to the manufacturer's instructions with the following of the constitutive chicken β-actin promoter (pGβAcβGID) (Sperisen modifications. Tailing was done using dATP. For PCR amplification, et al., 1992) . For IFN-γ inductions, cultures were split into halves after 5 μl of dA-tailed cDNA was added to 40 μl of amplification mix transfection and cultured in the absence or presence of IFN-γ (500 U/ml). containing 4.5 μl of 10ϫ synthesis buffer, 200 μM each dNTP, 25 pmol
The cells were cultured at 37°C for 48 h; total RNA was extracted with of gene-specific primer P 2 , 25 pmol of adapter primer ADXSC and Trizol reagent (Gibco-BRL) and treated with RNase-free DNase I 10 pmol of adapter primer XSCT17. The sample was incubated for (Boehringer). One μg of total RNA was used for the first strand cDNA 5 min at 95°C, then maintained at 80°C. Five μl of diluted Taq synthesis from a (dT) 20 primer with Superscript RNase H -reverse polymerase (2 U) was added, and the sample was amplified by 30 cycles transcriptase (50 U, Gibco-BRL) and 10 U of RNase inhibitor. β-Globin of 94°C for 45 s, 54°C for 25 s and 72°C for 2 min; the last extension cDNA was amplified by PCR: 1/10 of the reverse transcription product was for 10 min at 72°C. The sequences of the primers are: P 1 , 5Ј-was adjusted to 50 μl containing 5 μl of Vent 10ϫ buffer [100 mM GTCCAGTTCCGCGATATTGG-3Ј, P 2 , 5Ј-TCCCTGGTCTCTTCAKCl, 100 mM (NH 4 ) 2 SO 4 , 200 mM Tris-HCl pH 8.8, 20 mM MgSO 4 , TCA-3Ј; ADXSC, 5Ј-GACTCGAGTCGACATCG-3Ј; XSCT 17 , 5Ј-1% Triton X-100], 300 μM dNTP, 40 pmol of primer βGP5Ј (5Ј-GACTCGAGTCGACATCGAT 17 -3Ј. Conditions for RACE-PCR on TCCCCCAAAACAGACAGAATGG-3Ј), 40 pmol of primer βGP3Ј (5Ј-mouse RNA will be described elsewhere (L.Otten, V.Steimle, S.Bontron GTCACAGTGCAGTTCACTCAG-3Ј), 5% LB and 2 μCi of and B.Mach, in preparation).
[α-32 P]dCTP (Amersham). After 3 min at 95°C, 1 μl of Vent DNA polymerase (2 U, NEB) was added and the samples were amplified by 30 cycles of 94°C for 40 s, 59°C for 30 s, 72°C for 60 s. PCR Isolation of genomic clones products were denatured and separated by electrophoresis on a 6% A mouse genomic library in phage λgem11 (kindly provided by M.Aguet) polyacrylamide-8 M urea gel. mRNA-derived signals were quantified and a human genomic library in phage EMBL3 were screened with by PhosphorImager. The input ratios between the CIITA promoter random primed labelled CIITA cDNA probes using standard protocols plasmids and the reference plasmid were determined experimentally so (Sambrook et al., 1989) . Restriction maps were determined by complete as to yield comparable signals for the test (c) and reference (r) RT-PCR or partial digestions of overlapping clones and hybridization with specific bands. In order to permit comparison of signal ratios between different cDNA probes. Overlapping restriction fragments were cloned into experiments, a correction factor was applied for the quantification, pBluescript KS vector and the exons and their flanking regions were bringing all promoter to reference plasmid ratios to 10:1. sequenced by the dideoxy chain termination method using the T 7 G/ADeaza sequencing kit of Pharmacia.
